Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Review

New insights into antigen specific immunotherapy for chronic myeloid leukemia

Authors: Yangqiu Li, Chen Lin, Christian A Schmidt

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as an oncoprotein and a molecular and immunogenic target. Despite the success of targeted therapy using tyrosine kinase inhibitors (TKIs), CML remains largely incurable, most likely due to the treatment resistance of leukemic stem cells. Several immunotherapies have been developed for CML in different stages and relapse after allogeneic stem cell transplantation. In the this review, several specific immunotherapeutic approaches for CML, including vaccination and adoptive cellular immunotherapy, are discussed along with results from clinical trials, and the value of such immunotherapies in the era of imatinib and leukemia-associated antigens (LAAs), which are capable of inducing specific T cell responses and are appropriate target structures for the immunological targeting of CML cells, are also summarized.
Literature
1.
Cortes J, Kantarjian H: How I treat newly diagnosed chronic phase CML. Blood. 2012, 120 (7): 1390-1397. 10.1182/blood-2012-03-378919.PubMed
2.
Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010, 3: 47-10.1186/1756-8722-3-47.PubMedCentralPubMed
3.
Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186/1756-8722-4-6.PubMedCentralPubMed
4.
Rohon P: Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol. 2012, 96 (1): 1-9. 10.1007/s12185-012-1116-8.PubMed
5.
Sokal JE, Aungst CW, Snyderman M, Gomez G: Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules. Ann N Y Acad Sci. 1976, 277 (00): 367-383.PubMed
6.
Chen S, Yang L, Chen S, Li Y: TCR zeta chain expression in T cells from patients with CML. Hematology. 2009, 14 (2): 95-100. 10.1179/102453309X385241.PubMed
7.
Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000, 111 (3): 817-825. 10.1046/j.1365-2141.2000.02415.x.PubMed
8.
Li Y: Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008, 13 (5): 267-275. 10.1179/102453308X343482.PubMed
9.
Li Y, Geng S, Du X, Chen S, Yang L, Wu X, Li B, Schmidt CA, Przybylski GK: Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from patients with CML. Hematology. 2011, 16 (1): 43-49. 10.1179/102453311X12902908411634.PubMed
10.
Li Y, Geng S, Yin Q, Chen S, Yang L, Wu X, Li B, Du X, Schmidt CA, Przybylski GK: Decreased level of recent thymic emigrants in CD4+ and CD8 + T cells from patients with CML. J Transl Med. 2010, 8: 47-10.1186/1479-5876-8-47.PubMedCentralPubMed
11.
Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H: Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood. 1999, 94 (3): 1063-1069.PubMed
12.
Torelli GF, Paolini R, Tatarelli C, Soriani A, Vitale A, Guarini A, Santoni A, Foa R: Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2003, 120 (2): 201-208. 10.1046/j.1365-2141.2003.04044.x.PubMed
13.
Wang L, Zhu K, Zha X, Chen S, Yang L, Chen S, Li Y: Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol. 2010, 3: 14-10.1186/1756-8722-3-14.PubMedCentralPubMed
14.
Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y, Li Y: Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012, 31 (11): 1628-1635. 10.1089/dna.2012.1798.PubMedCentralPubMed
15.
Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M: Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother. 2007, 56 (6): 849-861. 10.1007/s00262-006-0232-9.PubMed
16.
Zha X, Chen S, Yang L, Li B, Chen Y, Yan X, Li Y: Characterization of the CDR3 structure of Vβ21 T cell clone in patients with P210BCR-ABL-positive CML and B-ALL. Hum Immunol. 2011, 72 (10): 798-804. 10.1016/j.humimm.2011.06.015.PubMed
17.
Müller L, Pawelec G: Chronic phase patients with CML possess T cells capable of recognising autologous tumour cells. Leuk Lymphoma. 2002, 43 (5): 943-951.PubMed
18.
Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009, 114 (8): 1528-1536. 10.1182/blood-2008-09-179697.PubMed
19.
Matte-Martone C, Venkatesan S, Tan HS, Athanasiadis I, Chang J, Pavisic J, Shlomchik WD: Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J Immunol. 2011, 187 (4): 1653-1663. 10.4049/jimmunol.1100311.PubMedCentralPubMed
20.
Ribas A: Tumor Immunotherapy Directed at PD-1. N Engl J Med. 2012, 366 (26): 2517-2519. 10.1056/NEJMe1205943.PubMed
21.
Vonka V: Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy. 2010, 2 (2): 227-224. 10.2217/imt.10.2.PubMed
22.
Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995, 85 (10): 2680-2684.PubMed
23.
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996, 87 (9): 3587-3592.PubMed
24.
Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000, 95 (5): 1781-1787.PubMed
25.
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004, 103 (3): 1037-1042.PubMed
26.
Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA: Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005, 90 (10): 1324-1332.PubMed
27.
Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F: Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. Nat Rev Clin Oncol. 2010, 7 (10): 600-603. 10.1038/nrclinonc.2010.141.PubMed
28.
Rojas JM, Knight K, Wang L, Clark RE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007, 21 (11): 2287-2295. 10.1038/sj.leu.2404858.PubMed
29.
Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J: Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009, 115 (17): 3924-3934. 10.1002/cncr.24468.PubMed
30.
Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J: Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine. 2010, 28 (37): 6028-6035. 10.1016/j.vaccine.2010.06.085.PubMedCentralPubMed
31.
Rosenfeld C, Cheever MA, Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003, 17 (7): 1301-1312. 10.1038/sj.leu.2402988.PubMed
32.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002, 99 (9): 3272-3279. 10.1182/blood.V99.9.3272.PubMed
33.
Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H: WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol. 2010, 85 (4): 358-360. 10.1111/j.1600-0609.2010.01497.x.PubMed
34.
Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M: Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002, 30 (9): 1029-1035. 10.1016/S0301-472X(02)00874-3.PubMed
35.
Greiner J, Schmitt M: Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol. 2008, 80 (6): 461-468. 10.1111/j.1600-0609.2008.01053.x.PubMed
36.
Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005, 174 (12): 8210-8218.PubMed
37.
Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M: Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer. 2003, 106 (2): 224-231. 10.1002/ijc.11200.PubMed
38.
Tschiedel S, Gentilini C, Lange T, Wölfel C, Wölfel T, Lennerz V, Stevanovic S, Rammensee HG, Huber C, Cross M, Niederwieser D: Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia. 2008, 22 (8): 1542-1550. 10.1038/leu.2008.107.PubMed
39.
Smahel M: Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother. 2011, 60 (12): 1655-1668. 10.1007/s00262-011-1126-z.PubMed
40.
Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y: Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol. 2011, 4: 21-10.1186/1756-8722-4-21.PubMedCentralPubMed
41.
Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ: Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia. 2008, 22 (9): 1721-172. 10.1038/leu.2008.161.PubMedCentralPubMed
42.
Al Qudaihi G, Lehe C, Dickinson A, Eltayeb K, Rasheed W, Chaudhri N, Aljurf M, Dermime S: Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematol Oncol Stem Cell Ther. 2010, 3 (1): 24-33.PubMed
43.
Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M: Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood. 2009, 113 (1): 66-74. 10.1182/blood-2008-06-164889.PubMed
44.
Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP: Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol. 2003, 171 (4): 1780-1789.PubMed
45.
Kharfan-Dabaja M, Ayala E, Lindner I, Cejas PJ, Bahlis NJ, Kolonias D, Carlson LM, Lee KP: Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunothe. 2005, 54 (1): 25-36. 10.1007/s00262-004-0562-4.
46.
Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, Goldman JM, Melo JV, Lechler RI, Bellantuono I, Ridley A, Lombardi G: Dendritic cells from patients with CML have altered actin organization, reduced antigen processing, and impaired migration. Blood. 2003, 101 (9): 3560-356. 10.1182/blood-2002-06-1841.PubMed
47.
Tong XM, Yao HP, Qian WB, Zhu LF, Fu ZH, Huang ZL, Jin J: The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells. Int J Lab Hematol. 2008, 30 (5): 372-381. 10.1111/j.1751-553X.2007.00986.x.PubMed
48.
Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlović S: Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006, 8 (3): 290-298. 10.1080/14653240600735743.PubMed
49.
Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Döhner K, Döhner H, Dörken B, Pezzutto A: Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl + chronic myeloid leukaemia. Br J Haematol. 2007, 137 (4): 297-306. 10.1111/j.1365-2141.2007.06547.x.PubMed
50.
Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF: Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood. 2009, 113 (19): 4681-4689. 10.1182/blood-2008-05-156471.PubMed
51.
Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, Wong KK: Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res. 2002, 62 (11): 3175-3183.PubMed
52.
Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H: Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res. 2003, 27 (9): 795-80. 10.1016/S0145-2126(03)00011-0.PubMed
53.
Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010, 16 (1): 338-347. 10.1158/1078-0432.CCR-09-2046.PubMedCentralPubMed
54.
Tao K, Li YJ, Wang D, Qi JY, Deng YP, Wang HX, Hu J, Feng WL: Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12. Cancer Biol Ther. 2011, 12 (10): 881-887. 10.4161/cbt.12.10.17674.PubMedCentralPubMed
55.
Grigg A, Szer J: Successful donor leukocyte infusion for chronic myeloid leukemia relapsing in accelerated phase after T cell-replete unrelated marrow transplantation. Bone Marrow Transplant. 1996, 18 (3): 647-648.PubMed
56.
Huang XJ: Hematopoietic stem cell transplantation in China: current status and prospects. Am J Blood Res. 2011, 1 (1): 90-99.PubMedCentralPubMed
57.
Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ: Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012, 119 (14): 3256-3262. 10.1182/blood-2011-09-380386.PubMed
58.
Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D, June CH: Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 2004, 33 (1): 53-60. 10.1038/sj.bmt.1704317.PubMed
59.
Kolb HJ, Schmid C, Barrett AJ, Schendel DJ: Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004, 103 (3): 767-776.PubMed
60.
Kondo Y, Shiobara S, Nakao S: Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro. Exp Hematol. 2001, 29 (4): 471-476. 10.1016/S0301-472X(01)00615-4.PubMed
61.
Lu YF, Gavrilescu LC, Betancur M, Lazarides K, Klingemann H, Van Etten RA: Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood. 2012, 119 (1): 273-284. 10.1182/blood-2011-01-331009.PubMedCentralPubMed
62.
Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS, McNiff J, Demetris AJ, Roopenian D, Kaech S, Shlomchik WD: Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood. 2011, 118 (22): 5965-5976. 10.1182/blood-2011-07-367011.PubMedCentralPubMed
63.
Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B: Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008, 112 (5): 1876-1885. 10.1182/blood-2008-04-150045.PubMedCentralPubMed
64.
Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009, 113 (10): 2245-2255. 10.1182/blood-2008-03-144071.PubMedCentralPubMed
65.
Crough T, Nieda M, Morton J, Bashford J, Durrant S, Nicol AJ: Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia. J Immunother. 2002, 25 (6): 469-475. 10.1097/00002371-200211000-00003.PubMed
66.
Sun JY, Senitzer D, Forman SJ, Chatterjee S, Wong KK: Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunol Immunother. 2003, 52 (12): 761-770. 10.1007/s00262-003-0415-6.PubMed
67.
Borchers S, Provasi E, Silvani A, Radrizzani M, Benati C, Dammann E, Krons A, Kontsendorn J, Schmidtke J, Kuehnau W, von Neuhoff N, Stadler M, Ciceri F, Bonini C, Ganser A, Hertenstein B, Weissinger EM: Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum Gene Ther. 2011, 22 (7): 829-841. 10.1089/hum.2010.162.PubMedCentralPubMed
68.
D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F: V gamma 9 V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010, 184 (6): 3260-3268. 10.4049/jimmunol.0903454.PubMed
69.
Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E: WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis. 2008, 40 (1): 113-116. 10.1016/j.bcmd.2007.06.018.PubMed
70.
Yin Q, Zha X, Yang L, Chen S, Zhou Y, Wu X, Li Y: Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol. 2011, 4: 2-10.1186/1756-8722-4-2.PubMedCentralPubMed
71.
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006, 314 (5796): 126-129. 10.1126/science.1129003.PubMedCentralPubMed
72.
Wang D, Zhang L, Li Y, Wang H, Xiao Q, Cao W, Feng W: Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells. Biotechnol Lett. 2012, 34 (7): 1193-1201. 10.1007/s10529-012-0896-5.PubMed
Metadata
Title
New insights into antigen specific immunotherapy for chronic myeloid leukemia
Authors
Yangqiu Li
Chen Lin
Christian A Schmidt
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-52

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

Stromal proteome expression profile and muscle-invasive bladder cancer research

Hypothesis

Targeted cellular ionic calcium chelation by oxalates: Implications for the treatment of tumor cells

Primary research

Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers

Primary research

Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall

Review

Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of ‘the dance macabre’

Editorial

Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits